202 related articles for article (PubMed ID: 35881476)
21. Diosmetin inhibits osteoclast formation and differentiation and prevents LPS-induced osteolysis in mice.
Shao S; Fu F; Wang Z; Song F; Li C; Wu ZX; Ding J; Li K; Xiao Y; Su Y; Lin X; Yuan G; Zhao J; Liu Q; Xu J
J Cell Physiol; 2019 Aug; 234(8):12701-12713. PubMed ID: 30515812
[TBL] [Abstract][Full Text] [Related]
22. Yukmijihwang-Tang Suppresses Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL)-Induced Osteoclast Differentiation and Prevents Ovariectomy (OVX)-Mediated Bone Loss.
Han SY; Kim YK
Molecules; 2021 Dec; 26(24):. PubMed ID: 34946658
[TBL] [Abstract][Full Text] [Related]
23. The differential expression of osteoprotegerin (OPG) and receptor activator of nuclear factor kappaB ligand (RANKL) in human osteoarthritic subchondral bone osteoblasts is an indicator of the metabolic state of these disease cells.
Kwan Tat S; Pelletier JP; Lajeunesse D; Fahmi H; Lavigne M; Martel-Pelletier J
Clin Exp Rheumatol; 2008; 26(2):295-304. PubMed ID: 18565252
[TBL] [Abstract][Full Text] [Related]
24. Systemic administration of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4)-Ig abrogates alveolar bone resorption in induced periodontitis through inhibition of osteoclast differentiation and activation: An experimental investigation.
Nakane S; Imamura K; Hisanaga R; Ishihara K; Saito A
J Periodontal Res; 2021 Oct; 56(5):972-981. PubMed ID: 34129238
[TBL] [Abstract][Full Text] [Related]
25. Andrographolide suppresses RANKL-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo.
Zhai ZJ; Li HW; Liu GW; Qu XH; Tian B; Yan W; Lin Z; Tang TT; Qin A; Dai KR
Br J Pharmacol; 2014 Feb; 171(3):663-75. PubMed ID: 24125472
[TBL] [Abstract][Full Text] [Related]
26. Arctigenin inhibits RANKL-induced osteoclastogenesis and hydroxyapatite resorption in vitro and prevents titanium particle-induced bone loss in vivo.
Wei G; Liang T; Wei C; Nong X; Lu Q; Zhao J
J Cell Biochem; 2019 Apr; 120(4):5367-5376. PubMed ID: 30317692
[TBL] [Abstract][Full Text] [Related]
27. Ferulic acid, a dietary polyphenol suppresses osteoclast differentiation and bone erosion via the inhibition of RANKL dependent NF-κB signalling pathway.
Doss HM; Samarpita S; Ganesan R; Rasool M
Life Sci; 2018 Aug; 207():284-295. PubMed ID: 29908722
[TBL] [Abstract][Full Text] [Related]
28. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.
Kim JY; Min JY; Baek JM; Ahn SJ; Jun HY; Yoon KH; Choi MK; Lee MS; Oh J
Bone; 2015 Oct; 79():242-51. PubMed ID: 26103094
[TBL] [Abstract][Full Text] [Related]
29. Low-density lipoprotein receptor deficiency causes impaired osteoclastogenesis and increased bone mass in mice because of defect in osteoclastic cell-cell fusion.
Okayasu M; Nakayachi M; Hayashida C; Ito J; Kaneda T; Masuhara M; Suda N; Sato T; Hakeda Y
J Biol Chem; 2012 Jun; 287(23):19229-41. PubMed ID: 22500026
[TBL] [Abstract][Full Text] [Related]
30. RANKL cytokine enhances TNF-induced osteoclastogenesis independently of TNF receptor associated factor (TRAF) 6 by degrading TRAF3 in osteoclast precursors.
Yao Z; Lei W; Duan R; Li Y; Luo L; Boyce BF
J Biol Chem; 2017 Jun; 292(24):10169-10179. PubMed ID: 28438834
[TBL] [Abstract][Full Text] [Related]
31. Osteoclast-gene expression profiling reveals osteoclast-derived CCR2 chemokines promoting myeloma cell migration.
Moreaux J; Hose D; Kassambara A; Reme T; Moine P; Requirand G; Goldschmidt H; Klein B
Blood; 2011 Jan; 117(4):1280-90. PubMed ID: 21097672
[TBL] [Abstract][Full Text] [Related]
32. Mechanisms of bone destruction in multiple myeloma.
Terpos E; Christoulas D; Gavriatopoulou M; Dimopoulos MA
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 28940410
[TBL] [Abstract][Full Text] [Related]
33. Water extract of the fruits of Alpinia oxyphylla inhibits osteoclast differentiation and bone loss.
Ha H; Shim KS; Kim T; Lee CJ; Park JH; Kim HS; Ma JY
BMC Complement Altern Med; 2014 Sep; 14():352. PubMed ID: 25249312
[TBL] [Abstract][Full Text] [Related]
34. The fungal metabolite (+)-terrein abrogates osteoclast differentiation via suppression of the RANKL signaling pathway through NFATc1.
Nakagawa S; Omori K; Nakayama M; Mandai H; Yamamoto S; Kobayashi H; Sako H; Sakaida K; Yoshimura H; Ishii S; Ibaragi S; Hirai K; Yamashiro K; Yamamoto T; Suga S; Takashiba S
Int Immunopharmacol; 2020 Jun; 83():106429. PubMed ID: 32222639
[TBL] [Abstract][Full Text] [Related]
35. Schisantherin A suppresses osteoclast formation and wear particle-induced osteolysis via modulating RANKL signaling pathways.
He Y; Zhang Q; Shen Y; Chen X; Zhou F; Peng D
Biochem Biophys Res Commun; 2014 Jul; 449(3):344-50. PubMed ID: 24845381
[TBL] [Abstract][Full Text] [Related]
36. Low levels of cadmium exposure affect bone by inhibiting Lgr4 expression in osteoblasts and osteoclasts.
Wang M; Liu J; Zhu G; Chen X
J Trace Elem Med Biol; 2022 Sep; 73():127025. PubMed ID: 35772369
[TBL] [Abstract][Full Text] [Related]
37. Coptisine inhibits RANKL-induced NF-κB phosphorylation in osteoclast precursors and suppresses function through the regulation of RANKL and OPG gene expression in osteoblastic cells.
Lee JW; Iwahashi A; Hasegawa S; Yonezawa T; Jeon WB; Cha BY; Nagai K; Woo JT
J Nat Med; 2012 Jan; 66(1):8-16. PubMed ID: 21656335
[TBL] [Abstract][Full Text] [Related]
38. Chloroquine reduces osteoclastogenesis in murine osteoporosis by preventing TRAF3 degradation.
Xiu Y; Xu H; Zhao C; Li J; Morita Y; Yao Z; Xing L; Boyce BF
J Clin Invest; 2014 Jan; 124(1):297-310. PubMed ID: 24316970
[TBL] [Abstract][Full Text] [Related]
39. Expression of osteoblast and osteoclast regulatory genes in the bone marrow microenvironment in multiple myeloma: only up-regulation of Wnt inhibitors SFRP3 and DKK1 is associated with lytic bone disease.
Kristensen IB; Christensen JH; Lyng MB; Møller MB; Pedersen L; Rasmussen LM; Ditzel HJ; Abildgaard N
Leuk Lymphoma; 2014 Apr; 55(4):911-9. PubMed ID: 23915193
[TBL] [Abstract][Full Text] [Related]
40. The high rate of bone resorption in multiple myeloma is due to RANK (receptor activator of nuclear factor-kappaB) and RANK Ligand expression.
Roux S; Mariette X
Leuk Lymphoma; 2004 Jun; 45(6):1111-8. PubMed ID: 15359989
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
